AMRXAmneal Pharmaceuticals, Inc.
Price
+103%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growing in the filings, the market undecided.
Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $796M in Q2 2026 (quarter ended Jun 30, 2026), up 9.9% from the same quarter a year earlier. That came with a gross margin of 42% and net income of $58M (7.2% of revenue). For the full year FY2025, revenue was $3.02B (+8.0% year on year) and net income $72M. Its largest product in Q2 2026 was Subtotal Therapeutic Classes at $149M, 19% of the disclosed total, ahead of Central Nervous System at 12%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 10, 2026The information set forth under the Introductory Note of this Report is incorporated into this.Material agreement entered · Form 8-K
- Aug 3, 2026On August 3, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 3 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as …Material agreement entered · Form 8-K
- Jul 30, 2026Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $770.3MThe company’s own SEC segment disclosure.
- Subtotal Therapeutic Classes$149.3M19%
- Central Nervous System$95.3M12%
- Distribution Service$86.9M11%
- Other Dosage Forms$81.6M11%
- Transdermal$67.0M9%
- Ephinephrine Auto Injector$62.2M8%
- Other (9)$227.9M30%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #16 of 41 by RyuScore